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Abstract
Background: Impaired lung function and insulin resistance have been associated and thereby have also been
indicated to be powerful predictors of cardiovascular mortality. Therefore, the co-existence of insulin resistance
and impaired lung function accompanied with cardiovascular risk factors should induce cardiovascular mortality
even in patients without known respiratory disease in a cumulative pattern. It could be useful to determine the
lung function of patients with insulin resistance in order to decrease cardiovascular mortality by means of taking
measures that minimize the risk of decline in lung function. However, no prior studies have been done on association
between insulin resistance and lung function in adults in Turkey. We aimed to determine if insulin resistance plays a
detrimental role in lung function in outpatients admitted to internal medicine clinics in adults from Turkey.
Methods: A total of 171 outpatients (mean ± SD) age: 43.1 ± 11.9) years) admitted to internal medicine clinics were
included in this single-center cross-sectional study, and were divided into patients with (n = 63, mean ± SD) age:
43.2 ± 12.5) years, 83.5 % female) or without (n = 108, mean ± SD) age: 43.0 ± 11.6) years, 93.5 % female) insulin
resistance. All patients were non-smokers. Data on gender, age, anthropometrics, blood pressure, blood biochemistry,
metabolic syndrome (MetS), and lung function tests were collected in each patient. Correlates of insulin resistance
were determined via logistic regression analysis.
Results: Insulin resistance was present in 36.8 % of patients. Logistic regression analysis revealed an increase in the
likelihood of having insulin resistance of 1.07 times with every 1-point increase in waist circumference, 1.01 times
with every 1-point increase in triglycerides, 0.93 times with every 1-point decrease in HDL (high density lipoprotein)
cholesterol, and 0.86 times with every 1-point decrease in percentage of FEV1/FVC pre (FEV1%pre: Forced expiratory
volume in the first second of expiration for predicted values; FVC%pre.: Forced vital capacity for predicted values).
Conclusions: Insulin resistance should also be considered amongst the contributing factors for decline in lung
function.
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Background
Impaired lung function, as measured by forced vital
capacity (FVC) or forced expiratory volume in the first
second (FEV1) [1] has been indicated as not only a
marker of premature death from all causes [2] but also has
been associated with excess adiposity, insulin resistance,
MetS, and type 2 diabetes mellitus. All these conditions
have also been indicated to be powerful predictors of
nonfatal ischemic heart disease and cardiovascular
mortality [1, 3–6].
Insulin resistance, beta cell dysfunction, impaired
glucose tolerance, and MetS ultimately lead to T2DM.
In other words, insulin resistance has been associated
with a range of cardiovascular risk factors including
dyslipidemia, essential hypertension, glucose intolerance,
and diabetes [7]. While reduced baseline FVC and FEV1
were reported to be independently related to a greater
risk of future development of MetS as well as new onset
type 2 diabetes mellitus [8], of which insulin resistance is
a core factor. Diabetes mellitus has also been considered
amongst the contributing factors for the development of
obstructive lung disease [8] and associated with greater
rates of decline in ventilatory function in longitudinal
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studies [4, 9]. However, the underlying mechanism is still
unclear.
Although impairment of lung function has been re-
ported to precede the development of diabetes [10, 11],
studies concerning the association of lung dysfunction
and hyperglycemia in individuals without diabetes, includ-
ing impaired fasting plasma glucose (FPG) and elevated
hemoglobin A1c (HbA1c) concentrations, revealed incon-
sistent results [10, 12–14]. While the exact mechanisms
by which a diabetic state leads to low lung function and
whether a low lung function is predictive of development
of diabetes remains to be elucidated [10], obesity, chronic
systemic inflammation, and insulin resistance have been
suggested as the common pathophysiologic determinants
[15–17].
Consideration of the reciprocal interaction between
lung function and diabetes mellitus in clinical practice has
been indicated to potentially improve outcomes as well as
to reduce the healthcare burden of both respiratory and
diabetic diseases [8] as well as insulin-resistant states.
Although as seen above, studies about the relation of
lung function, diabetes, and MetS are plentiful, but studies
about the relationship of insulin resistance and lung
function are scarce. There have not been any studies
evaluating lung functions in patients with insulin resist-
ance in Turkey. The aim of the present cross-sectional
study was to evaluate lung functions according to insulin
resistance states in outpatients without respiratory disease
admitted to internal medicine clinics in Turkey.
Methods
Study population
A total of 171 outpatients (mean (SD) age: 43.1 (11.9)
years) admitted to internal medicine outpatient clinics at
Istanbul Medeniyet University Goztepe Training and
Research Hospital, Istanbul for routine check-up who
gave informed consent were consecutively included to
the study between January and May 2011. Active smoker
or ex-smoker patients suffering from respiratory distress
or diagnosed with certain concomitant diseases such as
chronic obstructive respiratory disease, asthma, heart
failure, chronic liver disease, chronic kidney failure,
hypothyroidism, or any malignancy were excluded from
the study as were diabetic patients under treatment with
insulin or sulphonylureas. Patients were divided into two
groups including patients with (n = 63, mean ± SD) age:
43.2 ± 12.5) years, 83.5 % female) or without (n = 108,
mean ± SD) age: 43.0 ± 11.6) years, 93.5 % female) insulin
resistance. The study was approved by the Istanbul
Medeniyet University Goztepe Training and Research
Hospital Clinical Research Ethics Committee (Protocol
number and date: 8/D 28.12.2010).
Written informed consent was obtained from each
subject following a detailed explanation of the objectives
and protocol of the study, which was conducted in
accordance with the ethical principles stated in the
“Declaration of Helsinki”.
Biochemical analysis
Blood specimens were collected after 12–16 hours of
fasting. Roche Cobas 8000 analyzer was used for fasting
plasma glucose (intra-assay cv % 1.7 and 0.7 for low and
high concentrations respectively), triglycerides (intra-assay
cv % 0.9 and 0.6 for low and high concentrations respect-
ively), and HDL-C (intra-assay cv % 0.8 and 0.6 for low
and high concentrations respectively). Beckman Coulter
Unicel Dxl 800 (intra-assay cv % 5.6, 4.5, and 3.1 for nor-
mal, intermediate, and high concentrations respectively)
was used for insulin assay. Primus MRDV with HPLC
technique was used for HbA1c (intra-assay cv % 0.82, 0.91,
and 0.46 for normal, intermediate, and high concentrations
respectively; inter-assay cv % 2.91, 1.79, and 1.09 for nor-
mal, intermediate, and high concentrations respectively).
Study parameters
Data on gender, age, anthropometric measurements,
blood pressure, blood biochemistry (glycemic and lipid
parameters), criteria for MetS, and lung function tests
were collected in each patient with or without insulin re-
sistance. Correlates of insulin resistance was determined
via logistic regression analysis with inclusion of body mass
index, waist circumference, serum levels for HbA1c, HDL
cholesterol, and triglyceride along with FEV1 %, FEV1/
FVC % and FEF 25–75 % predicted values as the variables.
Anthropometric and blood pressure measurements
Weight and height were measured in light clothing with-
out shoes. The BMI was calculated by dividing the weight
by the square of the height (kg/m2). The waist circumfer-
ence was measured over the umbilicus at the narrowest
level between the costal margin and anterior superior iliac
spine. Blood pressure was measured by the same person
in each subject in supine position from both arms after at
least 10 minutes of rest, provided that the blood pressure
cuff covered about 80 % of the circumference of the upper
arm with the lower edge 2.5–3 cm above the elbow.
Insulin resistance
Insulin resistance was calculated using the homeostasis
model assessment insulin resistance index (HOMA-IR)
according to the following formula: fasting plasma
glucose (mmol/L) × fasting serum insulin (mU/mL)/
22.5 [18]. Insulin resistance was defined as HOMA-IR
index ≥2.5.
Metabolic syndrome
Definition of MetS was made based on ATPIII (adult
treatment panel III) criteria [19] with consideration of
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MetS in the presence of 3 of 5 of the listed character-
istics including abdominal obesity (waist circumfer-
ence of >94 cm in males and >80 cm in females),
elevated triglycerides (≥150 mg/dL, or concomitant
lipid lowering treatment), reduced HDL cholesterol
(<40 mg/dL in males and <50 mg/dL in females), ele-
vated blood pressure (≥130/≥85 mm Hg), and raised
fasting blood glucose (≥100 mg/dL, or concomitant
diabetes mellitus).
Lung function tests
Data on FEV1%, FVC %, FEV1/FVC %, peak expiratory
flow (PEF %), forced expiratory flow (FEF 25–75 %), and
forced inspiratory vital capacity (FIVC %) were collected in
each subject via forced spirometry and static respiratory
volume measurements performed by trained staff using
Vitalograph Pneumotrac 6800 (Vitalograph Ltd., Ireland).
All tests were carried out following guidelines proposed by
the European Respiratory Society [20]. The theoretical
values proposed by Roca et al. [21] and by the European
Respiratory Society for static volumes were applied
for spirometry [20]. Spirometric measurements of
FVC and FEV1, percentage of FVC for predicted
values (FVC%pre), and percentage of FEV1 for pre-
dicted values (FEV1%pre) were used as markers of re-
strictive lung dysfunction. The FEV1/FVC ratio was
calculated by dividing the measured FEV1 by the
measured FVC as a marker of obstructive lung dys-
function [22, 23].
The ratio of FEV1 to FVC (FEV1/FVC) was calculated,
and a value ≥70 % was considered as normal. According
to a modified classification of the Global Initiative for
Chronic Obstructive Lung Disease (GOLD), patients
were classified as having normal spirometric values (FEV1/
FVC ≥70 %, FVC ≥80 %), obstructive lung dysfunction
(FEV1/FVC <70 %) and restrictive lung dysfunction
(FVC <80 % predicted, FEV1/FVC ≥70 %) [24].
Statistical analysis
Statistical analysis was made using computer software
NCSS 2007 version 07.1.14 SPSS version 20.0.0.1 (SPSS
Inc. Chicago, IL, USA). Categorical data were analyzed
using Chi-square test. Numerical data were analyzed was
using Student’s t-test and one-way ANOVA for variables
with normal distribution, while Mann–Whitney U and
Kruskal–Wallis tests were used for non-normally distrib-
uted variables. Best logistic regression model for insulin
resistance was selected based on lowest Akaike informa-
tion criterion (AIC) and Bayesian information criterion
(BIC) values. Data were expressed as “median (min-max)”
and percent (%) where appropriate. A p < 0.05 was consid-
ered statistically significant (Additional file 1).
Results
Demographics and anthropometrics in study groups
Patients with and without insulin resistance were
homogenous in terms of gender and age. Insulin resistance
was present in 36.8 % of patients. Mean ± SD values for
BMI (body mass index) (37.0 ± 5.8 vs. 33.4 ± 5.2 kg/m2, p <
0.001), percentage of patients with BMI of ≥35 kg/m2
(61.9 vs. 28.7 %, p < 0.001), and Mean ± SD values for
waist circumference (107.0 ± 11.5 vs. 98.3 ± 9.8 cm, p <
0.001) were significantly higher in patients with than with-
out insulin resistance (Table 1).
Glycemic parameters in study groups
Mean ± SD levels of FBG (118.5 ± 37.8 vs. 102.2 ±
32.0 mg/dL, p < 0.001), HbA1c (6.3 ± 1.2 vs. 6.0 ± 1.0 %, p
= 0.013), insulin (15.7 ± 6.1 vs. 6.9 ± 2.3 μU/ml, p < 0.001),
and HOMA-IR (4.5 ± 1.8 vs. 1.7 ± 0.5, p < 0.001) were
significantly higher in patients with than without in-
sulin resistance (Table 1).
Lipid parameters in study groups
Patients with insulin resistance were determined to have
significantly lower levels of HDL cholesterol (45.6 ± 8.9
vs. 52.9 ± 10.9 mg/dL, p < 0.001) and higher levels of tri-
glycerides (192.4 ± 101.3 vs. 127.8 ± 65.9 mg/dL, p < 0.001)
when compared to patients without insulin resistance
(Table 1).
MetS in study groups
MetS was noted in a significantly higher percentage of
patients with than without insulin resistance (82.5 vs.
52.8 %, p < 0.001) with markedly higher overall mean ±
SD) number of positive diagnostic criteria (4.0 ± 1.0 vs.
3.0 ± 1.0, p < 0.001) and a higher percentage of patients
meeting the criteria of raised blood glucose/diabetes
(61.9 vs. 38.0 %, p = 0.002), reduced HDL cholesterol
(69.8 vs. 46.3 %, p = 0.003), and raised triglycerides (61.9
vs. 34.3 %, p < 0.001) in the former group (Table 1).
Lung function in study groups
Mean ± SD values for FEV1/FVC (103.5 ± 6.4 vs. 106.3 ±
5.2, p =0.004) and FEF 25–75 (103.1 ± 23.1 vs. 112.7 ± 21.8,
p =0.020) were significantly lower in patients with than
without insulin resistance. The percentage of patients with
abnormal lung function was significantly higher in the insu-
lin resistance group (30.2 vs. 16.6 %, p =0.039) (Table 1).
Correlates of insulin resistance
Lung function evaluation revealed abnormal findings in
one-third of our patients with insulin resistance, almost
two-fold higher than the rate noted in patients without in-
sulin resistance. Univariate analysis revealed that waist
circumference (p < 0.001), body mass index (p < 0.001), tri-
glycerides (p < 0.001), and HbA1c (p =0.038) levels were
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Table 1 Demographic and clinical characteristics with respect to insulin resistance
Insulin resistance p value
Total Absent Present with vs. without
insulin resistance(n = 171) (n = 108) (n = 63)
Demographics Mean (SD)
Age (year) 43.1 (11.9) 43.0 (11.6) 43.2 (12.5) 0.9251
Gender n (%)
Male 16 (9.4) 7 (6.5) 9 (14.3) 0.0912
Female 155 (90.6) 101 (93.5) 54 (85.7)
Anthropometrics
Height (cm) Mean (SD) 160.0 (7.7) 159.1 (6.8) 161.7 (8.9) 0.110b
Weight (kg) 160.0 (7.7) 84.4 (12.7) 96.0 (16.9) <0.001b
Body mass index (kg/m2)
Overall score Mean (SD) 34.7 (5.7) 33.4 (5.2) 37.0 (5.8) <0.001b
≤29.9 n (%) 30 (17.5) 25 (23.1) 5 (7.9) <0.0012
30-34.9 71 (41.5) 52 (48.1) 19 (30.2)
≥35 70 (40.9) 31 (28.7) 39 (61.9)
Waist circumference (cm) 101.5 (11.3) 98.3 (9.8) 107.0 (11.5) <0.001b
Blood pressure (mmHg) Mean (SD)
Systolic 131.7 (18.7) 130.6 (19.3) 133.4 (17.5) 0.220b
Diastolic 81.0 (11.3) 80.2 (11.4) 82.4 (11.1) 0.235b
Glycemic parameters Mean (SD)
FBG (mg/dL) 108.2 (35.1) 102.2 (32.0) 118.5 (37.8) <0.001b
HbA1c (%) 6.1 (1.1) 6.0 (1.0) 6.3 (1.2) 0.013b
Insulin (μU/ml) 10.1 (5.9) 6.9 (2.3) 15.7 (6.1) <0.001b
HOMA-IR 2.7 (1.8) 1.7 (0.5) 4.5 (1.8) <0.001b
Lipid parameters Mean (SD)
LDL cholesterol (mg/dL) 121.5 (35.3) 122.8 (35.2) 119.1 (35.6) 0.299b
HDL cholesterol (mg/dL) 50.2 (10.8) 52.9 (10.9) 45.6 (8.9) <0.001b
Total cholesterol (mg/dL) 198.6 (41.4) 197.7 (41.2) 200.1 (42.0) 0.719b
Triglyceride (mg/dL) 151.6 (86.3) 127.8 (65.9) 192.4 (101.3) <0.001b
Metabolic syndrome
Present n (%) 109 (63.7) 57 (52.8) 52 (82.5) <0.0012
Diagnostic criteria (#) Mean (SD) 3.0 (1.0) 3.0 (1.0) 4.0 (1.0) <0.001b
Waist circumference (Male>94 cm, Female>80 cm) 171 (100.0) 108 (100.0) 63 (100.0) -
Blood pressure (≥130/≥85 mm Hg) 98 (57.3) 56 (51.9) 42 (66.7) 0.0592
Fasting blood glucose (≥100 mg/dL, or concomitant diabetes mellitus) 80 (46.8) 41 (38.0) 39 (61.9) 0.0022
HDL cholesterol (Male < 40 mg/dL, Female <50 mg/dL) 94 (55.0) 50 (46.3) 44 (69.8) 0.0032
Triglycerides (≥150 mg/dL) 76 (44.4) 37 (34.3) 39 (61.9) <0.0012
Spirometric findings Mean (SD)
FEV1%pre (%) 93.6 (11.9) 95.2 (10.9) 91.0 (13.2) 0.111
b
FEV1/FVC%pre (%) 105.3 (5.8) 106.3 (5.2) 103.5 (6.4) 0.004
b
PEF%pre (%) 88.3 (15.5) 89.6 (14.1) 86.0 (17.4) 0.281
b
FEF 25-75%pre (%) 109.2 (22.7) 112.7 (21.8) 103.1 (23.1) 0.020
b
FVC%pre (%) 89.1 (11.3) 89.7 (10.6) 88.0 (12.5) 0.587
b
FIVC%pre % 84.3 (23.2) 86.1 (24.7) 81.3 (20.6) 0.119
b
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positively associated, while HDL cholesterol (p < 0.001),
and predicted values for FEV1 % (p = 0.028), FEV1/
FVC % (p = 0.003), and FEF 25–75 % (p = 0.009),
were negatively associated with insulin resistance.
Age-adjusted analysis also revealed similar findings
(Table 2).
Logistic regression analysis with inclusion of BMI,
waist circumference, HbA1c, HDL cholesterol, and
triglycerides, as well as predicted values for FEV1/
FVC% and FEF 25–75 % revealed an increase in the
likelihood of having insulin resistance by 1.07 times
(95 % CI 1.02–1.13, p = 0.011) with every 1-point in-
crease in waist circumference, 1.01 times (95 % CI
1.0–1.01, p = 0.032) with every 1-point increase in
triglycerides, 0.93 times (95 % CI 0.89-0.98, p = 0.004)
with every 1-point decrease in HDL cholesterol, and 0.86
times (95 % CI 0.76–0.97, p = 0.012) with every 1-
point decrease in percentage of FEV1/FVC predicted
value. Age-adjusted analysis also revealed similar findings
(Table 3).
Table 1 Demographic and clinical characteristics with respect to insulin resistance (Continued)
Respiratory function n (%)
Normal 134 (78.4) 90 (83.3) 44 (69.8) 0.0392
Abnormal 37 (21.6) 18 (16.7) 19 (30.2)
HDL high density lipoprotein, LDL low density lipoprotein, FBG fasting blood glucose, FEV1%pre forced expiratory volume in the first second of expiration for
predicted values, FVC%pre forced vital capacity for predicted values, PEF%pre peak expiratory flow for predicted values, FEF%pre forced expiratory flow for predicted
values; FIVC%pre: forced inspiratory vital capacity for predicted values
aStudent’s t-test, 2X 2 test, bMann–Whitney U test
Table 2 Univariate logistic regression analysis for the correlates of insulin resistance
Overall Age-adjusted analysis
Odds ratio 95 % confidence interval p value Odds ratio 95 % confidence interval p value
Minimum Maximum Minimum Maximum
Gender (being female) 0.42 0.15 1.18 0.099 0.40 0.14 1.17 0.095
Age (year) 1.00 0.98 1.03 0.924 - - - -
Height (cm) 1.05 1.003 1.090 0.037 1.05 1.00 1.09 0.032
Waist circumference (cm) 1.08 1.04 1.12 <0.001 1.08 1.05 1.12 <0.001
Body weight (kg) 1.06 1.03 1.08 <0.001 1.06 1.03 1.09 <0.001
Body mass index (kg/m2) 1.13 1.06 1.20 <0.001 1.13 1.06 1.20 <0.001
Systolic blood pressure (mmHg) 1.01 0.99 1.03 0.347 1.01 0.99 1.03 0.334
Diastolic blood pressure (mmHg) 1.02 0.99 1.05 0.218 1.02 0.99 1.05 0.218
HbA1c (%) 1.37 1.02 1.84 0.038 1.45 1.04 2.02 0.031
Fasting blood glucose (mg/dL) 1.01 1.00 1.02 0.007 1.02 1.01 1.03 0.004
Insulin (μU/ml) 2.32 1.76 3.04 <0.001 2.43 1.82 3.24 <0.001
HDL-cholesterol (mg/dL) 0.92 0.89 0.96 <0.001 0.92 0.89 0.96 <0.001
LDL-cholesterol (mg/dL) 1.00 0.99 1.01 0.510 1.00 0.99 1.01 0.504
Total cholesterol (mg/dL) 1.00 0.99 1.01 0.703 1.00 0.99 1.01 0.709
Triglyceride (mg/dL) 1.01 1.01 1.02 <0.001 1.01 1.01 1.02 <0.001
Metabolic syndrome criteria # 1.84 1.40 2.43 <0.001 2.10 1.53 2.88 <0.001
Metabolic syndrome diagnosis 4.23 1.99 8.97 <0.001 4.83 2.19 10.66 <0.001
FEF 25-75%pre (%) 0.98 0.97 1.00 0.009 0.98 0.97 1.00 0.008
FEV1%pre (%) 0.97 0.94 1.00 0.028 0.97 0.94 1.00 0.028
FEV1/FVC%pre (%) 0.91 0.86 0.97 0.003 0.91 0.86 0.97 0.003
FIVC%pre (%) 0.99 0.98 1.01 0.301 0.99 0.96 1.02 0.342
FVC%pre (%) 0.99 0.96 1.01 0.342 0.99 0.98 1.01 0.307
PEF%pre (%) 0.99 0.97 1.01 0.152 0.99 0.97 1.01 0.152
Abnormal lung function test 2.16 1.03 4.52 0.041 2.29 1.05 4.96 0.036
FEV1%pre forced expiratory volume in the first second of expiration for predicted values, FVC%pre forced vital capacity for predicted values, PEF%pre peak expiratory
flow for predicted values, FEF%pre forced expiratory flow for predicted values FIVC%pre forced inspiratory vital capacity for predicted values
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Discussion
Our findings revealed that insulin resistance was present in
36.8 % of outpatients admitted to internal medicine clinics,
with higher rates for dysglycemia and dyslipidemia and
thereby a higher prevalence of MetS in patients with than
without insulin resistance. Insulin resistance was positively
associated with waist circumference, BMI, and serum levels
of triglycerides and HBA1c, while it was negatively corre-
lated with HDL cholesterol levels and lung function param-
eters including predicted values for FEV1%, FEV1/FVC%,
and FEF25–75 %. Multiple logistic regression analysis re-
vealed waist circumference and triglyceride levels as the
positive determinants while HDL levels and FEV1/FVC%
were negative determinants of insulin resistance.
Accordingly, our findings in a cohort of outpatients ad-
mitted to internal medicine clinics demonstrate that im-
paired lung function, with FEV1/FVC% in particular, can
be used to predict development of insulin resistance
in agreement with data from prior studies indicating
that lower lung function was associated with a state
of insulin resistance, both longitudinally [6] and cross-
sectionally [25].
Cross-sectional analyses that investigated the rela-
tionship between lung dysfunction and dysglycemia in
individuals without diabetes found conflicting results
[10, 12–14]. In a past study conducted with 5346 men in
Japan with no history of diabetes or lung dysfunction, it
was reported that a 10-point decrease in percentage of
FEV1 predicted value was associated with an increased
hazard ratio of 1.21 for diabetes after adjustment for
demographic factors and body mass index [10]. FEV1
and FVC were reported to be inversely associated
with insulin resistance and the prevalence of type 2
diabetes in female participants older than 60 years in
the British Women’s Heart and Health Study [5],
while in a younger population of non-diabetic mor-
bidly obese women, a negative correlation of HOMA-
IR with FEV1, FEF25–75, and FVC was reported [15].
The diminished lung function in patients with insulin
resistance as well as identification of FEV1/FVC decline
as the significant determinant of increased likelihood of
insulin resistance in our study population seem consist-
ent with past studies indicating that the risk for develop-
ing diabetes was inversely related to prior lung function
[26, 27], in addition to an association between low lung
function and both measures of insulin resistance and
type 2 diabetes [5, 13, 28].
Hence, in our study population, that insulin resistance
was negatively correlated with lung function seems
notable and supports the suggestion that the metabolic
pathways related to insulin resistance are crucial in initi-
ating lung abnormalities in type 2 diabetic patients [15].
Our findings indicate FEV1/FVC% to be a significant
and strong risk factor for development of insulin resist-
ance, which emphasizes the more pronounced role of
FEV1% decline than FVC% decline. Hence, our findings
emphasize the likelihood of insulin resistance to be
causally related to obstructive rather than restrictive re-
spiratory patterns while supporting the statement that
pre-diabetes and abdominal obesity rather than diabetes
are causally related to a restrictive respiratory pattern
[24]. Notably, reduced baseline FVC and FEV1 were
reported to be independently related to a greater risk of
future development of MetS [1], while a shared pathophysi-
ology has been suggested to underlie this association with
consideration of reduced lung volumes as the potential
markers of lower physical endurance in patients at risk for
the development of MetS [8]. Garcia-Larsen et al. stated
that reduced FVC was related to HOMA-IR in both gen-
ders, although FVC and FEV1 were negatively related to
MS in the young adult study population and in men [29].
Mechanisms involved in the insulin resistant state have
been considered likely to be responsible for predisposing
individuals to a lower maximal attained lung function or to
an early initiation of the decline in lung function [28]. The
mean age of our cases was 43.1 ± 11.9 years, with smokers,
Table 3 Multivariate logistic regression analysis for the correlates of insulin resistance
Overall Age-adjusted analysis
Odds ratio 95 % confidence interval p value Odds ratio 95 % confidence interval p value
Minimum Maximum Minimum Maximum
Waist circumference (cm) 1.07 1.02 1.13 0.011 1.08 1.02 1.14 0.009
Body mass index (kg/m2) 1.03 0.94 1.13 0.541 1.03 0.93 1.14 0.552
HDL cholesterol (mg/dL) 0.93 0.89 0.98 0.004 0.93 0.89 0.97 0.002
Triglyceride (mg/dL) 1.01 1.00 1.01 0.032 1.01 1.00 1.01 0.040
HbA1c (%) 1.22 0.81 1.83 0.340 1.09 0.69 1.71 0.717
FEV1/FVC%pre (%) 0.86 0.76 0.97 0.012 0.84 0.74 0.95 0.006
FEF 25-75%pre (%) 1.00 0.98 1.03 0.934 1.00 0.98 1.03 0.761
FEV1%pre forced expiratory volume in the first second of expiration for predicted values, FVC%pre forced vital capacity for predicted values, FEF%pre forced expiratory
flow for predicted values
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ex-smokers, and patients with respiratory distress and con-
comitant respiratory diseases excluded from the study; the
majority of our study population was female (90.6 %). In
fact, the estrogen and progesterone that appear after
menopause increase susceptibility to both insulin resist-
ance and respiratory dysfunction along with the normal
physiological decline in lung function after the ages of 30–
35 years for most people [15, 28]. In this regard, persist-
ence of the relationship between insulin resistance and
lung function in our patients even after the age-adjusted
univariate and multivariate logistic regression analyses
seems notable.
Given the BMI of ≥35 kg/m2 in 61.9 % and presence
of MetS in 82.5 % of patients with insulin resistance and
abdominal obesity in all patients with MetS in the
present study, our findings strongly correlate with the
data from a past study in obese patients that reported a
lower FEV1/FVC ratio, indicating airway obstruction, in
patients with than without MetS [24] and support the
demonstrated relationship between abdominal circum-
ference and the FEV1/FVC ratio [30].
Indeed, the cellular mechanisms underlying the insulin
resistant state have been suggested to explain the observed
relationship between low lung function with either cardio-
vascular disease or all-cause mortality in many epidemio-
logic studies [28]. Notably, low lung function among
diabetics was reported to also be an independent predictor
of all-cause mortality [11]. FEV1 was reported specifically
as an independent predictor of all-cause mortality and a
strong risk factor for cardiovascular disease, stroke, and
lung cancer [31]. Additionally, airflow obstruction as de-
fined by an FEV1/FVC less than 0.70 has also been linked
with increased coronary artery disease morbidity and mor-
tality in large population studies [32].
Our findings revealed that impairment of lung function
might be regarded as an early manifestation of insulin
resistance and that determination of FEV1/FVC should
serve to detect subjects at risk for developing insulin re-
sistance, which has been accused, at least partially, for the
association of increased risk of mortality from coronary
heart disease (CHD) in subjects with decreased baseline
ventilatory function [33]. Therefore our findings are in line
with the statement that early detection of insulin resist-
ance may lead to effective interventions aimed at primary
prevention of the syndrome as well as the risk of mortality
from CHD [1].
The present study has a number of limitations that
should be taken into account in evaluating the results.
First, this was a cross-sectional study and, therefore, a
causal link between insulin resistance and impaired lung
function cannot be drawn. Second, the relatively small
sample size might prevent us from projecting our results
to the entire population. Third, exclusion of diabetic pa-
tients under treatment with insulin or sulphonylureas
may have introduced selection bias given the likelihood
of systematic exclusion of subjects with the most severe
insulin resistance. Nevertheless, given that lung dysfunc-
tion as part of the pre-diabetic state has not been fully
elucidated [10], our findings would contribute to a com-
prehension of the interaction between lung function and
insulin resistance in an outpatient population.
Conclusion
Our findings in a population of outpatients admitted to in-
ternal medicine clinics without a known respiratory dis-
order revealed the presence of insulin resistance in 36.8 %,
with higher rates for dysglycemia and dyslipidemia and
thereby higher prevalence of MetS in patients with than
without insulin resistance. Increases in waist circumference
and triglyceride levels and decreases in HDL cholesterol
and percent value for predicted FEV1/FVC were associated
with increased likelihood of insulin resistance. While the
exact mechanisms by which a state of insulin resistance
leads to low lung function as well as the value of introdu-
cing lung function measures into an insulin resistance pre-
diction model remain to be elucidated, our findings
emphasize that FEV1/FVC% is low, thereby indicating an
obstructive respiratory pattern in the interaction between
lung dysfunction and insulin resistance. Based on these
findings, it seems reasonable to advocate the measurement
and control of lung function along with implication of
programs aimed at reduction in obesity to decrease the
likelihood of insulin resistance.
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